Epstein-Barr Virus BZLF1 Gene, a Switch from Latency to Lytic Infection, is Expressed As an Immediate-early Gene After Primary Infection of B Lymphocytes

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2006 Nov 3

PMID 17079287

Citations 67

Authors

Wangrong Wen

Dai Iwakiri

Koji Yamamoto

Seiji Maruo

Teru Kanda

Kenzo Takada

Affiliations

Soon will be listed here.

Abstract

We demonstrate here that the Epstein-Barr virus (EBV) BZLF1 gene, a switch from latent infection to lytic infection, is expressed as early as 1.5 h after EBV infection in Burkitt's lymphoma-derived, EBV-negative Akata and Daudi cells and primary B lymphocytes. Since BZLF1 mRNA is expressed even when the cells are infected with EBV in the presence of anisomycin, an inhibitor of protein synthesis, its expression does not require prerequisite protein synthesis, indicating that BZLF1 is expressed as an immediate-early gene following primary EBV infection of B lymphocytes.

Citing Articles

Comparison of Nanopore with Illumina Whole Genome Assemblies of the Epstein-Barr Virus in Burkitt Lymphoma.

Kim I, Kim Jr I, Fola A, Puig E, Maina T, Hui S medRxiv. 2025; .

PMID: 40061313 PMC: 11888525. DOI: 10.1101/2025.02.21.25322471.

Epstein-Barr virus replication within differentiated epithelia requires pRb sequestration of activator E2F transcription factors.

Schaal D, Amucheazi A, Jones S, Nkadi E, Scott R J Virol. 2024; 98(10):e0099524.

PMID: 39291960 PMC: 11494884. DOI: 10.1128/jvi.00995-24.

EBV-induced T-cell responses in EBV-specific and nonspecific cancers.

Zhang Q, Xu M Front Immunol. 2023; 14:1250946.

PMID: 37841280 PMC: 10576448. DOI: 10.3389/fimmu.2023.1250946.

Changes in SUMO-modified proteins in Epstein-Barr virus infection identifies reciprocal regulation of TRIM24/28/33 complexes and the lytic switch BZLF1.

De La Cruz-Herrera C, Tatham M, Siddiqi U, Shire K, Marcon E, Greenblatt J PLoS Pathog. 2023; 19(7):e1011477.

PMID: 37410772 PMC: 10353822. DOI: 10.1371/journal.ppat.1011477.

Contribution of Epstein-Barr Virus Lytic Proteins to Cancer Hallmarks and Implications from Other Oncoviruses.

Dorothea M, Xie J, Yiu S, Chiang A Cancers (Basel). 2023; 15(7).

PMID: 37046781 PMC: 10093119. DOI: 10.3390/cancers15072120.

References

Evans T, Jacquemin M, Farrell P . Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle. Virology. 1995; 206(2):866-77. DOI: 10.1006/viro.1995.1009. View

Sinclair A, Farrell P . Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J Virol. 1995; 69(9):5461-8. PMC: 189395. DOI: 10.1128/JVI.69.9.5461-5468.1995. View

Cayrol C, Flemington E . The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. EMBO J. 1996; 15(11):2748-59. PMC: 450210. View

Chen H, Lee J, Wang Y, Huang D, Ambinder R, Hayward S . The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity. Proc Natl Acad Sci U S A. 1999; 96(16):9339-44. PMC: 17784. DOI: 10.1073/pnas.96.16.9339. View

Hong G, Kumar P, Wang L, Damania B, Gulley M, Delecluse H . Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. J Virol. 2005; 79(22):13984-92. PMC: 1280197. DOI: 10.1128/JVI.79.22.13984-13992.2005. View

Savard M, Belanger C, Tardif M, Gourde P, Flamand L, Gosselin J . Infection of primary human monocytes by Epstein-Barr virus. J Virol. 2000; 74(6):2612-9. PMC: 111749. DOI: 10.1128/jvi.74.6.2612-2619.2000. View

Dreyfus D, Nagasawa M, Kelleher C, Gelfand E . Stable expression of Epstein-Barr virus BZLF-1-encoded ZEBRA protein activates p53-dependent transcription in human Jurkat T-lymphoblastoid cells. Blood. 2000; 96(2):625-34. View

Maruo S, Yang L, Takada K . Roles of Epstein-Barr virus glycoproteins gp350 and gp25 in the infection of human epithelial cells. J Gen Virol. 2001; 82(Pt 10):2373-2383. DOI: 10.1099/0022-1317-82-10-2373. View

Nanbo A, Inoue K, Takada K . Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J. 2002; 21(5):954-65. PMC: 125896. DOI: 10.1093/emboj/21.5.954. View

10.

Iwakiri D, Takada K . Phosphatidylinositol 3-kinase is a determinant of responsiveness to B cell antigen receptor-mediated Epstein-Barr virus activation. J Immunol. 2004; 172(3):1561-6. DOI: 10.4049/jimmunol.172.3.1561. View

11.

zur Hausen H, ONEILL F, Freese U, Hecker E . Persisting oncogenic herpesvirus induced by the tumour promotor TPA. Nature. 1978; 272(5651):373-5. DOI: 10.1038/272373a0. View

12.

Takada K . Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer. 1984; 33(1):27-32. DOI: 10.1002/ijc.2910330106. View

13.

Countryman J, Miller G . Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci U S A. 1985; 82(12):4085-9. PMC: 397939. DOI: 10.1073/pnas.82.12.4085. View

14.

Takada K, Shimizu N, Sakuma S, Ono Y . trans activation of the latent Epstein-Barr virus (EBV) genome after transfection of the EBV DNA fragment. J Virol. 1986; 57(3):1016-22. PMC: 252835. DOI: 10.1128/JVI.57.3.1016-1022.1986. View

15.

Jenson H, Rabson M, Miller G . Palindromic structure and polypeptide expression of 36 kilobase pairs of heterogeneous Epstein-Barr virus (P3HR-1) DNA. J Virol. 1986; 58(2):475-86. PMC: 252934. DOI: 10.1128/JVI.58.2.475-486.1986. View

16.

Takada K, Ono Y . Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol. 1989; 63(1):445-9. PMC: 247705. DOI: 10.1128/JVI.63.1.445-449.1989. View

17.

Rooney C, Howe J, Speck S, Miller G . Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol. 1989; 63(4):1531-9. PMC: 248385. DOI: 10.1128/JVI.63.4.1531-1539.1989. View

18.

Farrell P, Rowe D, Rooney C, Kouzarides T . Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J. 1989; 8(1):127-32. PMC: 400780. DOI: 10.1002/j.1460-2075.1989.tb03356.x. View

19.

Allday M, Crawford D, Griffin B . Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J Gen Virol. 1989; 70 ( Pt 7):1755-64. DOI: 10.1099/0022-1317-70-7-1755. View

20.

Flemington E, Speck S . Identification of phorbol ester response elements in the promoter of Epstein-Barr virus putative lytic switch gene BZLF1. J Virol. 1990; 64(3):1217-26. PMC: 249236. DOI: 10.1128/JVI.64.3.1217-1226.1990. View